Oncolytics Biotech Inc. Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Sep 8, 2025 · CIK: 1129928
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, sec-filing
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH INC. (ONCY) filed a 6-K, standard foreign issuer report.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on September 8, 2025, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on the company's reporting status as a foreign private issuer, which is important for investors tracking regulatory compliance and disclosures.
Risk Assessment
Risk Level: low — This is a routine regulatory filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the 6-K report
- 001-38512 (company) — SEC File Number for Oncolytics Biotech Inc.
- September 2025 (date) — Reporting period for the Form 6-K
- 20250908 (date) — Filing date of the Form 6-K
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is submitted to the SEC to provide information that the issuer would be required to make public in its home country, or that it may otherwise make public.
What is the filing date of this Form 6-K?
The Form 6-K was filed on September 8, 2025.
What is the SEC file number for Oncolytics Biotech Inc.?
The SEC file number for Oncolytics Biotech Inc. is 001-38512.
What is the primary business of Oncolytics Biotech Inc.?
Oncolytics Biotech Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Does Oncolytics Biotech Inc. file annual reports on Form 20-F or 40-F?
Oncolytics Biotech Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-09-08 07:30:25
Filing Documents
- form6kcrcupdate.htm (6-K) — 17KB
- oncycrc.htm (EX-99.1) — 17KB
- 0001129928-25-000074.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date September 8, 2025 Kirk Look Chief Financial Officer